Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib Plus Gemcitabine vs Gemcitabine in Persistent or Relapsed Ovarian Cancer
NCT01610206Phase 2Completed
- Start
- Sep 2012
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pazopanib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms). Primary endpoints: Progression-Free Survival at 3 years and Overall Survival at 3 years. Started Sep 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01610206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610206.